NCT04046445 - Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 22, 2019

Primary Completion Date

May 31, 2025

Study Completion Date

August 31, 2025

Conditions

Colorectal CancerMSSStage IV Colon CancerStage IV Rectal CancerMetastatic Colorectal CancerLiver Metastasis Colon Cancer

Interventions

DRUG

ATP128

5-6 SC injections

DRUG

BI 754091

≥ 7 IV infusions

DRUG

VSV-GP128

1 single IV injection

Trial Locations (12)

Geneva University Hospitals, Geneva

University Hospital Antwerpen, Edegem

University Hospital Leuven, Leuven

University Hospital Zurich, Zurich

NYU Langone Health, New York

Weill Cornell Medicine, New York

Duke Cancer Institute, Durham

University Medicine Mainz, Mainz

University of Texas, MD Anderson Cancer Center, Houston

University of Colorado Anschutz Medical Campus, Aurora

Honor Health Institute, Scottsdale

University of Southern California, Los Angeles